

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	10/063,557
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al.
Art Unit	1642
Examiner	David J. Blanchard
Attorney Docket No.	GNE.3230R1C39

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
DB	1	5,407,799	04-18-1995	Studier	
↓	2	6,498,235 B2	12-24-2002	Sheppard, et al.	
↓	3	6,645,499 B1	11-11-2003	Lal, et al.	
DB	4	6,730,502 B2	05-04-2004	Van Hijum, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
DB	5	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
↓	6	The 1991 Boehringer Mannheim Biochemicals Catalog, page 557, 1991.	
↓	7	BURGESS, et al. 1990. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. <i>The Journal of Cell Biology</i> , 111:2129-2138.	
↓	8	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
DB	9	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	

Examiner Signature *David J. Blanchard*Date Considered *6/6/05*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 2 OF 2

Application No.	10/063,557
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al.
Art Unit	1642
Examiner	David J. Blanchard
Attorney Docket No.	GNE.3230R1C39

MAR 22 2005

## NON PATENT LITERATURE DOCUMENTS

Initials	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
DB	10	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	
	11	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	12	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	13	LAZAR, et al. 1988. Transforming growth factor $\alpha$ : Mutation of aspartic acid 47 and leucine 48 results in different biological activities. <i>Molecular and Cellular Biology</i> , 8(3):1247-1252.	
	14	LI, et al. 1980. $\beta$ -Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities. <i>Proc. Natl. Acad. Sci. USA</i> , 77(6):3211-3214.	
	15	LIN, et al. 1975. Structure-function relationships in glucagon: Properties of highly purified Des-His <sup>1</sup> -, Monoiodo-, and [Des-Asn <sup>28</sup> , Thr <sup>29</sup> ](homoserine lactone <sup>27</sup> )-glucagon. <i>Biochemistry</i> , 14(8):1559-1563.	
	16	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	17	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	18	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	19	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	20	SCHWARTZ, et al. 1987. A superactive insulin: [B10-aspartic acid]insulin(human). <i>Proc. Natl. Acad. Sci. USA</i> , 84:6408-6411.	
	21	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
DB	22	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1351252\_1:dmb  
031805

Examiner Signature


Date Considered

6/6/05


\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/063,557
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1642
	Examiner	David J. Blanchard
SHEET 1 OF 1	Attorney Docket No.	GNE.3230R1C39

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,395,306 B1	05-28-2002	Cui, et al.	
	4	6,414,117 B1	07-02-2002	Levinson, D. A.	
		6,737,522 B2	05-18-2004	Sundick, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	6	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	

1556093\_1:dmb  
040805

Examiner Signature 	Date Considered 6/6/05
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.